Lion Biotechnologies to Present New Interim Data

Lion Biotechnologies (LBIO) said early Thursday it plans to present new interim data from the first cohort of its ongoing phase 2 study of LN-144 for the treatment of metastatic melanoma at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago next month.

The data is from nine patients in cohort one who were infused as of Jan. 31. These advanced metastatic melanoma patients are a median age of 56, and all had prior anti-PD1 as well as anti-CTLA4 therapy and 67% had received three or more prior therapies. The results show a 33% objective response rate; responses were observed in patients with tumors carrying wild type or BRAF mutations; eight of nine patients received all six doses of IL-2 per protocol; the most common non-hematologic grade 3-4 TEAE was hypophosphatemia; no neurotoxicity of grade 3 or higher was reported; and, there were no deaths or discontinuations due to SAEs related to study treatment.

Leave a Comment